Media

FIERCE BIOTECH: As Elicio Therapeutics awaits a phase 2 readout of its lymph node-targeting therapeutic cancer vaccine in humans, the biotech has published fresh preclinical data showing the same tech boosted the efficacy of T cell receptor-modified T-cell (TCR-T) therapy in mice.

Dylan J. Drakes, Abdulraouf M. Abbas, et al.
Cancer Immunology Research (An AACR Journal)
January 25, 2024

ACIR: Colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) have a low survival rate, low infiltration of tumor-specific tumor-infiltrating lymphocytes (TIL), infrequent neoantigen mutations, and checkpoint inhibitors are largely ineffective in PDAC and subtypes of CRC. Common mutations in the oncogenes driver KRAS (mKRAS) however can serve as immunotherapy targets.

Zev A. Wainberg, Vincent Chung, et al.
Presented at the ASCO Gastrointestinal Cancer Symposium
January 18-20, 2024

CLINICAL TRIALS ARENA: The study aims to evaluate the antitumor activity of the vaccine in pancreatic ductal adenocarcinoma (PDAC) patients.

TARGETED ONCOLOGY: The first patient with KRAS-mutated pancreatic ductal adenocarcinoma (PDAC) has been dosed with ELI-002 7P in the phase 2 AMPLIFY-7P study (NCT05726864), according to Elicio Therapeutics, Inc.

MEDICAL NEWS TODAY: Researchers are reporting that a new vaccine could help prevent the reemergence of colorectal and pancreatic cancer in high-risk people who have previously undergone cancer treatment.

Shubham Pant, Zev A. Wainberg, et al.
Nature Medicine
January 09, 2024

INDEPENDENT: A new vaccine has shown “promising” signs of being able to prevent relapse of specific types of pancreatic and bowel cancers for people who have previously had surgery.

HEALTHDAY: Patients with the most common form of pancreatic cancer could benefit from an experimental therapeutic vaccine, a small new clinical trial shows.